- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00726973
Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
A Pilot Study With Reduced Fluence Photodynamic Therapy With Visudyne Ranibizumab VS. Ranibizumab Only to Treat Exudative AMD
The purposes of this study is to determine if combination reduced fluence photodynamic therapy and Ranibizumab has:
Similar efficacy to Ranibizumab (Lucentis) alone. The ability to reduce the number of intravitreal injection of Ranibizumab or a 13 month period The ability to reduce the number of PDT treatments. The study will also collect information on the safety of combination therapy and single therapy.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This will be a 13 month prospective, blinded, randomized sham controled parallel safety study. There will be 2 treatment arms.
Arm 1 will receive reduced fluence PDT at baseline followed immediately by an intravitreal injection of Lucentis. Subjects in arm 1 will receive 2 additional injections of Ranibizumab (Lucentis) over the next 2 months. Starting at month 3, they will receive combination reduced fluence PDT and intravitreal Ranibizumab (Lucentis) if they develop recurrence of the subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness > 100 microns compared to the best prior thickness measure on OCT. Patients will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab (Lucentis) every 3 months thereafter. Group 1 patients are eligible for treatment with combination reduced fluence PDT and Ranibizumab (Lucentis) at any point at the 3 month time point or thereafter. After month 3, if patients were not eligible for combined therapy (<3 months since the last combination therapy) and have >2 lines of vision loss or > 100 microns of increased retinal thickness on OCT compared to most recent measure at their monthly visit, they would be eligible for an injection of Ranibizumab (Lucentis) as monotherapy. Thereafter, subjects will have combination therapy if retreatment criteria were met and it has been >3 months since the last PDT treatment.
Study arm 2 will receive 3 monthly intravitreal injections of Ranibizumab (Lucentis). Following month 2, they will be eligible for re-treatment with Ranibizumab (Lucentis) if retreatment criteria are met (same criteria as study arm 1). At intervals of no less than 3 months from the previous sham PDT, they will receive sham PDT if retreatment criteria are met.
Typ studiów
Faza
- Nie dotyczy
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male / Female > 50 years of age
- FA diagnosis of CNV lesions as described above
- Have a best corrected visual acuity letter score in the study eye between 72-24 letters (approximately 20/40 to 20/320) using ETDRS chart measured at 4 meters
- Central retinal (including lesion) thickness greater than or equal to 250 microns as measured by OCT
- Subretinal hemorrhage making up less than 50% of total lesion size and sparing the fovea
- Sufficiently clear ocular media including the lens to allow photography of the retina
- Written informed consent has been obtained.
Exclusion Criteria:
- Dense subfoveal hemorrhage (>50% of the lesion)
- Tear or rip of the retina pigment epithelium, idiopathic parafoveal telangiectasis or serous pigment epithelial detachment without CNV
- Geographic atrophy involving the foveal center
- Subretinal fibrotic scar in the study eye greater than 25% of the lesion
- Presence of any condition in study eye other than AMD known to be associated with CNV
- History diabetic retinopathy or diabetic macular edema
- Previous pars plana vitrectomy
- Previous photodynamic therapy in the study eye
- Previous photodynamic therapy in the fellow eye with resultant choroidal hypoperfusion
- Previous intravitreal anti-VEGF or steroid injection in the study eye
- Previous thermal subfoveal laser treatment in study eye
- Anticipated need for ocular surgery in the study eye during the 13 month study period
- Known allergy or sensitivity to the study medication(s) its components, diagnostic agents used during the study (Fluorescein, dilation drops) or other agents required for the study procedures (ie: povidone iodine)
- Porphyria or other porphyrin sensitivity
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: 1
Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
|
Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab.
For 2 months injected intravitreal Ranibizumab will be given.
At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab.
If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
Inne nazwy:
|
Aktywny komparator: 2
Ranibizumab monotherapy
|
3 monthly intravitreal injections of Ranibizumab monotherapy.
After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Primary efficacy will be proportion of subjects with best corrected visual acuity improvement of 15 or more letters from baseline and wil visual acuity stabilization, less than 15 letter loss from baseline at 13 months
Ramy czasowe: at conclusion of subject enrollment
|
at conclusion of subject enrollment
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Mean change in ETDRS from baseline, number of Ranibizumab treatments w/reduced fluence PDT, proportion of patients with 6 lines of vision loss
Ramy czasowe: at conclusion of subject enrollment
|
at conclusion of subject enrollment
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Jeffrey L Marx, M.D., Lahey Clinic Medical Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2006-085
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Ranibizumab
-
University of Campania "Luigi Vanvitelli"Zakończony
-
University of Illinois at ChicagoGenentech, Inc.WycofaneJaskra | Jaskra neowaskularna | Jaskra o nowym początku | Nowo rozpoznana jaskra neowaskularna
-
Hawaii Pacific HealthGenentech, Inc.ZakończonyPolipoidalna waskulopatia naczyniówkowa | PCVStany Zjednoczone
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.ZakończonyCukrzycowy obrzęk plamkiArgentyna, Meksyk
-
Instituto de Olhos de GoianiaZakończony
-
Vista KlinikZakończonyZwyrodnienie plamki żółtej związane z wiekiem | Neowaskularyzacja naczyniówkowaSzwajcaria
-
NovartisZakończonyCukrzycowy obrzęk plamkiSzwajcaria
-
Sun Yat-sen UniversityZakończonyPolipoidalna waskulopatia naczyniówkowaChiny
-
AbbVieRekrutacyjnyCNV | AMD | nAMD | Mokre AMD | Mokre zwyrodnienie plamki żółtej związane z wiekiem | wAMDStany Zjednoczone
-
NovartisZakończonyZwyrodnienie plamki żółtej związane z wiekiemSzwajcaria